Biblio Discovery — Demo Discovery Service

5 results for "Francesca Gay"

Showing 1–5 · 2.80 seconds · RSS

  1. Journal Article Full text

    Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

    Mattia D’Agostino; David Allan Cairns; Juan José Lahuerta et al.

    Journal of Clinical Oncology · 2022 · English · OpenAlex Scopus

    PURPOSE: Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are at intermediate-risk according to the Revised International Staging system (R-ISS), the standard-of-care risk stratification model. Moreover, chromosome 1q…

  2. Journal Article Full text

    LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    María‐Victoria Mateos; Katja Christina Weisel; Valerio De Stefano et al.

    Leukemia · 2022 · English · OpenAlex Scopus

    Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first…

  3. Journal Article Full text

    Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Pieter Sonneveld; Meletios Athanasios Dimopoulos; Mario Boccadoro et al.

    New England Journal of Medicine · 2023 · English · OpenAlex Scopus

    BACKGROUND: Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of transplantation-eligible patients with newly…

  4. Journal Article Full text

    Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

    Michèle Cavo; Francesca Gay; Meral Beksaç et al.

    The Lancet Haematology · 2020 · English · OpenAlex Scopus

    Background The emergence of highly active novel agents has led some to question the role of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent consolidation therapy in newly diagnosed multiple myeloma. We therefore compared autologous HSCT with bortezomib–melphalan–prednisone…